You are here
FDA Approves Isolagen's Request for Special Protocol Assessment
HOUSTON, May 23 /PRNewswire-FirstCall/ -- Isolagen, Inc. today announced that the U.S. Food and Drug Administration, or FDA, has approved Isolagen's request for a Special Protocol Assessment, or SPA, relating to the design of two pivotal Phase III clinical trials to be conducted by Isolagen in support of registration of the Isolagen Process for the treatment of nasolabial folds and glabellar lines. The company believes that the FDA's action will significantly reduce the risks associated with conducting its pivotal Phase III clinical trials to provide evidence of efficacy and safety sufficient for license application.
An SPA is an understanding that the FDA concludes with a sponsor company to resolve issues with regard to Phase III clinical trial design, in contemplation of the subsequent filing by that sponsor of an application for a license. The grant by the FDA of a request for an SPA is not commonplace. In the SPA process, the FDA reviews the design and size of a proposed Phase III program and provides comments regarding the adequacy of the clinical trial design to support a claim of efficacy in an approvable Biologic License Application, or BLA. The FDA's comments are binding on its review decision, except in limited circumstances, such as when a substantial scientific issue essential to determining the safety and efficacy of a product candidate is identified after the Phase III program commences. There can be no assurance that the Company's efforts to obtain a BLA will be successful, however, trials conducted on an SPA are frequently associated with successful license application because many of the design concerns that arise in connection with a clinical trial are resolved in advance by the sponsor and the FDA.
Source: Isolagen, Inc.